首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 感染疾病 > 全球抗感染藥市場（抗真菌劑、抗菌劑、抗病毒劑）
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

全球抗感染藥市場（抗真菌劑、抗菌劑、抗病毒劑）

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

出版商 Kalorama Information
出版日期 2009年10月 商品編碼 101995
內容資訊 英文 250 pages
價格
US $ 3500 PDF by E-mail (Single User License)
US $ 3900 Hard Copy
US $ 4200 PDF by E-mail (Dept User License)
US $ 7000 PDF by E-mail (Global Site License)


全球抗感染藥市場（抗真菌劑、抗菌劑、抗病毒劑） 是由出版商Kalorama Information在2009年10月所出版的。 這份英文市場調查報告書包含250 pages 價格從美金3500起跳。

簡介

本報告書內容包括：抗真菌劑、抗菌劑、抗病毒劑等個別區隔市場的現況及預測、現在已上市的產品及後期開發階段產品的概要、以美國、歐洲為主的全球抗感染症藥市場的統計資料。內容綱要摘記如下：

第1章 實施概要

第2章 介紹及產業動向

  • 概要
  • 病原菌介紹
  • 全球人口統計
  • 抗傳染藥的抗藥性
  • HIV動向

第3章 抗真菌劑

  • 概要
  • 真菌感染種類
  • 抗真菌劑概要
  • 市場概要
  • 市場規模及預測
  • 產品別市場
  • 地區別市場
  • 治療別市場分析
  • 競爭分析

第4章 抗菌劑

  • 概要
  • 抗菌生物分類
  • 抗菌的範圍
  • 細菌抗藥性
  • 抗菌治療的原理
  • 合併療法及預防藥使用
  • 細菌傳染的統計資料
  • 細菌傳染風險
  • 抗菌產品概要
  • 市場規模及預測
  • 產品別市場
  • 地區別市場
  • 治療別市場分析
  • 競爭分析
  • 主要產品

第5章 抗病毒劑

  • 概要：病毒介紹
  • 病原菌性病毒事例
  • 病毒功能及生命的歷史
  • DNA病毒複製
  • RNA病毒複製
  • 逆轉錄病毒
  • 病毒防禦
  • 針對宿主細胞侵入及避免宿主反應的病毒計畫
  • HIV及AIDS
  • 病毒傳染的統計資料
  • 抗病毒產品
  • 其他抗病毒產品
  • 市場概要
  • 總體市場規模及預測
  • 市場分析
  • 競爭分析
  • 主要產品

第6章 市場摘要

  • 市場規模及預測
  • 區隔別市場

第7章 企業介紹

  • Introduction
  • Abbott Laboratories
  • AstraZeneca/MedImmune
  • Bayer Schering Pharma AG
  • Bristol-Myers Squibb
  • 第一三共
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
  • Schering-Plough Corporation
  • Wyeth

附錄

圖表

目錄

Abstract

The anti-infective market is at a critical juncture. For the past 60 years, antibiotic drugs have turned bacterial infections into treatable conditions rather than the life-threatening scourges they once were. But the effectiveness of many antibiotics is waning dramatically, as more and more types of bacteria become resistant to them.

This Kalorama Information The World Market for Anti-Infectives considers the anti-infective drug market as it faces challenges with resistance and generic competition.

The report focuses on three key segments of treatment:

  • Antifungals (Allylamines, Azoles,Polyene Macrolides and Other Antifungals)
  • Antibacterials (Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Carbopenems, Miscellaneous)
  • Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors)

For each category and each subsegment, current market and forecast is provided. The report covers both currently marketed and late stage development products.. Revenues for each segment were generated using dollar sales for each product.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe.

As part of its coverage the report provides:

  • Overview
  • Description of Products on the Market
  • Review of Products in Late Stage Development
  • Market Estimates and Forecasts
  • Competitive Analysis of Leading Providers
  • Regional Breakdown of Antifungal, Antibacterial and Antiviral Market (US, Europe and Asia)
  • Market Share of Antifungal, Antibacterial and Antiviral Market

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Total Size and Growth of the Market
  • Issues and Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

  • Overview
  • Introduction to Pathogens
  • Demographics of the World
  • Anti-Infective Drug Resistance
    • Antibiotic Abuse
    • Antibiotic Use in Agriculture
    • Resistance in Select Populations
    • Children
    • The Elderly
    • Compromised Individuals
    • Measures for Reducing Resistance
    • Antibiotic Cycling
    • Antibiotic Education
    • Screening Hospitalized patients
  • HIV Trends
    • Infection Rates
    • HIV and Women
    • Costs and Funding of HIV Treatment
    • Access to HIV/AIDS Treatment
  • Manufacturer and Marketer Trends
    • Trends in Partnerships and Alliances
    • Developers Trends
    • Trends in Rx-to-OTC Switches

CHAPTER THREE: ANTIFUNGAL DRUGS

  • Overview
  • Types of Fungal Infections
    • Superficial
    • Systemic
    • Histoplasmosis
    • Coccidioidomycosis
    • Blastomycosis
    • Fungal Infection Statistics
    • Fungal Infection Risk
  • Description of Antifungal Products
    • Systemic Antifungals
    • Allylamines
    • Azoles
    • Polyene Macrolides
    • Systemic Miscellaneous Antifungals
    • Topical Antifungals
    • Allylamines
    • Topical Azoles
    • Topical Polyene Macrolides
    • Topical Miscellaneous Antifungals
  • Market Overview
  • Total Market Size and Forecast
  • Antifungal Market by Product Type
    • Allylamines
    • Azoles
    • Polyene Macrolides
    • Other Antifungals
  • Antifungal Market by Geographical Region
  • Market Analysis by Treated Condition
  • Competitive Analysis

CHAPTER FOUR: ANTIBACTERIAL DRUGS

  • Overview
  • Classification of Antibacterial Organisms
  • Antimicrobial Spectrum
  • Bacterial Resistance
  • Principles of Anti-bacterial Therapy
    • Infecting Organism
    • Antibiotic Sensitivity Testing
    • Site of Infection
    • Host Defenses and Organ Function
    • Antibiotic Pharmacokinetics
    • Monitoring Therapy
  • Combination Therapy and Prophylactic Use
  • Bacterial Infection Statistics
  • Bacterial Infection Risk
  • Description of Antibacterial Products
    • Cephalosporins
    • Macrolides
    • Penicillins
    • Quinolones
    • Sulfonamides
    • Tetracyclines
    • Carbopenems
    • Systemic Miscellaneous Antibiotics
  • Market Overview
  • Total Market Size and Forecast
  • Antibacterial Market by Product Type
  • Cephalosporins
  • Macrolides
  • Penicillins
  • Quinolones
  • Sulfonamides
  • Tetracyclines
  • Carbopenems
  • Other Products
  • Antibacterial Market by Geographical Region
  • Market Analysis by Treated Condition
  • Competitive Analysis
  • Leading Products

CHAPTER FIVE: ANTIVIRAL DRUGS

  • Overview: Introduction to Viruses
  • Examples of Pathogenic Viruses
  • Virus Function and Life History
  • Replication in DNA Viruses
  • Replication of RNA Viruses
  • Replication in Retroviruses
  • Host Defenses Against Viruses
  • Viral Ploys to Invade Host Cells and Circumvent Host Responses
    • Invasion of Host Cells
    • Subversion of the Immune Response
    • Avoidance of Immune Detection and Attack by Killer Cells
  • HIV and AIDS
  • Viral Infection Statistics
  • Description of Antivirals Products
    • Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
    • Nucleoside Reverse Transcriptase Inhibitors
    • Combination Nucleoside Reverse Transcriptase Inhibitors
    • Nucleotide Analogue Reverse Transcriptase Inhibitors
    • Non-Nucleoside Reverse Transcriptase Inhibitors
    • Combination Non-Nucleoside Reverse Transcriptase Inhibitors
    • DNA Polymerase Inhibitors
    • Protease Inhibitors
  • Other Antivirals
  • Market Overview
  • Total Market Size and Forecast
    • Antiviral Market by Product Type
    • Nucleoside Analogs
    • Protease Inhibitors
    • Other Antivirals
    • Antiviral Market by Geographical Region
  • Market Analysis by Treated Condition
  • Competitive Analysis
  • Leading Products

CHAPTER SIX: MARKET SUMMARY

  • Total Market Size and Forecast
  • Market by Segment

CHAPTER SEVEN: CORPORATE PROFILES

  • Introduction
  • Abbott Laboratories
  • AstraZeneca/MedImmune
  • Bayer Schering Pharma AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson Group
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
  • Schering-Plough Corporation
  • Wyeth

APPENDIX: LIST OF MAJOR PROVIDERS

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2006-2013
  • Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2009

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

  • Table 2-1: Estimated World Population by Age and Geographical Region, 2009
  • Figure 2-1: Estimated World Population by Age and Geographical Region, 2009
  • Table 2-2: Worldwide HIV/AIDS Infections
  • Table 2-3: Women Living with HIV/AIDS, by Region 1990 to 2007 (Percent)
  • Table 2-4: AIDS Resource Needs (US$ billion), 2006-2008
  • Table 2-5: Antiretroviral Access for HIV Infected Individuals by Region, 2005*
  • Table 2-6: Anti-Infective Drugs in Development by Developer
  • Table 2-7: Anti-infectives Ingredients Transferred from Rx-to-OTC

CHAPTER THREE: ANTIFUNGAL DRUGS

  • Table 3-1: Estimated World and U.S. Incidence of Fungal Infections
  • Figure 3-1: Estimated World and U.S. Incidence of Leading Fungal Infections
  • Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
  • Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
  • Table 3-3: Systemic Allylamines
  • Table 3-4: Systemic Azoles
  • Table 3-5: Systemic Polyene Macrolides
  • Table 3-6: Systemic Miscellaneous Antifungals
  • Table 3-7: Topical Allylamines
  • Table 3-8: Topical Azoles
  • Table 3-9: Topical Polyene Macrolides
  • Table 3-10: Topical Miscellaneous Antifungals
  • Table 3-11: The World Market for Antifungal Drugs 2006-2013
  • Figure 3-3: The World Market for Antifungal Drugs 2006-2013
  • Table 3-12: Antifungal Drug Market by Type 2006-2013
  • Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2006-2013
  • Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2009 and 2013
  • Table 3-13: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2006-2013
  • Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2006-2013
  • Table 3-14: World Antifungal Market Estimated Products Sales by Infection Type, Sales in Millions, 2009
  • Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2009
  • Table 3-15: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
  • Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers 2006-2009
  • Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2009
  • Table 3-16: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009
  • Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2006-2009

CHAPTER FOUR: ANTIBACTERIAL DRUGS

  • Table 4-1: Antibiotics with Difficult Penetration
  • Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections
  • Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections
  • Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
  • Figure 4-2: World Population at Risk for Serious Bacterial Infections Secondary to Chronic Diseases by Selected Geographical Region, 2008-2009
  • Table 4-4: Currently Available Cephalosporin Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-5: Currently Available Macrolide Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-6: Currently Available Penicillin Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-7: Currently Available Quinolone Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-8: Currently Available Sulfonamide Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-9: Currently Available Tetracycline Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-10: Currently Available Carbopenems (Type, Brand, and Manufacturer)
  • Table 4-11: Currently Available Other Miscellaneous Antibiotics (Type, Brand, and Manufacturer)
  • Table 4-12: The World Market for Antibacterial Drugs 2006-2013
  • Figure 4-3: The World Market for Antibacterial Drugs 2006-2013
  • Table 4-13: Antibacterial Drug Market by Type 2006-2013
  • Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type 2006-2013
  • Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2009 and 2013
  • Table 4-14: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2006-2013
  • Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2006-2013
  • Table 4-17: World Antibacterial Market Estimated Products Sales by Infection Type
  • Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2009
  • Table 4-18: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
  • Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2006-2009
  • Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2009
  • Table 4-19: World Market for Antibacterial Drugs Estimated Sales of Select Products 2006-2009
  • Figure 4-10: World Market for Antibacterial Drugs Estimated Sales of Top Ten Products 2006-2009

CHAPTER FIVE: ANTIVIRAL DRUGS

  • Table 5-1: Host Cell Receptors
  • Table 5-2: Estimated World and U.S. Incidence of Viral Infections
  • Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections
  • Table 5-3: Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
  • Table 5-4: Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
  • Table 5-5: Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
  • Table 5-6: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
  • Table 5-7: Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
  • Table 5-8: Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)
  • Table 5-9: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
  • Table 5-10: Currently Available Miscellaneous Antivirals (Type, Brand, and Manufacturer)
  • Table 5-11: The World Market for Antiviral Drugs 2006-2013
  • Figure 5-2: The World Market for Antiviral Drugs 2006-2013
  • Table 5-12: Antiviral Drug Market by Type 2006-2013
  • Figure 5-3: The World Market for Antiviral Drugs Revenues by Type 2006-2013
  • Figure 5-4: The World Market for Antiviral Drugs Revenues by Type 2009 and 2013
  • Table 5-13: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2006-2013
  • Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2006-2013
  • Table 5-14: World Antiviral Market Estimated Products Sales by Infection Type
  • Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2009
  • Table 5-15: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009
  • Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2006-2009
  • Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2009
  • Table 5-16: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009
  • Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2006-2009

CHAPTER SIX: MARKET SUMMARY

  • Table 6-1: The Global Market for Anti-Infectives by ProductSegment, 2006-2013
  • Figure 6-1: The World Market for Anti-Infective Drugs 2006-2013
  • Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2009
  • Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2013
Back to Top